Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruxolitinib + peginterferon alfa-2a
- Development stage
- Phase 2
- Lead developer
- French Innovative Leukemia Organisation
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This combination therapy, often referred to as the RUXOPeg regimen, consists of the JAK1/JAK2 inhibitor ruxolitinib and the pegylated cytokine peginterferon alfa-2a. It was evaluated in a Phase 1/2 clinical trial (NCT02742324) sponsored by the French Innovative Leukemia Organisation (FILO) for the treatment of patients with primary or secondary myelofibrosis, including post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Ruxolitinib works by inhibiting the Janus kinase signaling pathway, which is often overactive in myeloproliferative neoplasms, while peginterferon alfa-2a exerts antiproliferative and immunomodulatory effects. The combination aims to improve clinical outcomes and potentially achieve molecular responses by targeting different aspects of the disease biology through synergistic mechanisms.
- Other names
- ruxolitinib and peg-interferon alpha-2aRUXOPeg regimen
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on ruxolitinib + peginterferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruxolitinib + peginterferon alfa-2a.